ACRS
ACRS clinical trials: Aclaris Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Aclaris Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 37
- Trials linked
- 34
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ACRS on the catalyst calendar · ACRS registry changes
- Primary completion Mar 2029Sponsor estimatePhase 2NCT07935590Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical...Aclaris Therapeutics, Inc. · Lichen PlanusRecruitingACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 21, 2026ActualPhase 2NCT07011706ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisAclaris Therapeutics, Inc. · Atopic DermatitisActive, not recruitingACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2023ActualPhase 2NCT05279417ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)Aclaris Therapeutics, Inc. · Rheumatoid ArthritisCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 13, 2025ActualPhase 2NCT06585202Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic DermatitisAclaris Therapeutics, Inc. · Atopic DermatitisCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2022ActualPhase 2NCT05216224ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)Aclaris Therapeutics, Inc. · Hidradenitis SuppurativaCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 6, 2023ActualPhase 2NCT05511519Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic ArthritisAclaris Therapeutics, Inc. · Psoriatic ArthritisTerminatedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 26, 2023ActualPhase 2NCT05432596Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic DermatitisAclaris Therapeutics, Inc. · Atopic DermatitisCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 8, 2021ActualPhase 2NCT04598269Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic DermatitisAclaris Therapeutics, Inc. · Atopic DermatitisCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 25, 2021ActualPhase 2NCT04524858Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)Aclaris Therapeutics, Inc. · Cryopyrin-Associated Periodic SyndromeTerminatedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 4, 2021ActualPhase 2NCT04247815Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RAAclaris Therapeutics, Inc. · Rheumatoid ArthritisCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2019ActualPhase 2NCT03468855A Study of ATI-50002 Topical Solution for the Treatment of VitiligoAclaris Therapeutics, Inc. · VitiligoCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2015ActualPhase 2NCT02260180Study of A-101 for the Treatment of Seborrheic KeratosisAclaris Therapeutics, Inc. · Seborrheic KeratosisCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2019ActualPhase 3NCT03812510Safety Study of A-101 Topical Solution for the Treatment of Common WartsAclaris Therapeutics, Inc. · Common WartCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2019ActualPhase 2NCT03495817A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical SolutionAclaris Therapeutics, Inc. · Androgenetic AlopeciaCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 21, 2019ActualPhase 3NCT03691831A Study of A-101 Topical Solution for the Treatment of Common WartsAclaris Therapeutics, Inc. · Common WartCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2019ActualPhase 2NCT03759340ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)Aclaris Therapeutics, Inc. · Alopecia AreataTerminatedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 20, 2019ActualPhase 3NCT03687372Study of A-101 Topical Solution for the Treatment of Common WartsAclaris Therapeutics, Inc. · Common WartCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 6, 2019ActualPhase 2NCT03594227ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia TotalisAclaris Therapeutics, Inc. · AlopeciaCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 20, 2019ActualPhase 2NCT03315689Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)Aclaris Therapeutics, Inc. · Alopecia Universalis (AU)CompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 18, 2019ActualPhase 2NCT03354637A Study of ATI-50002 Topical Solution for the Treatment of Alopecia AreataAclaris Therapeutics, Inc. · Alopecia AreataTerminatedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 8, 2019ActualPhase 2NCT03224598A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa NigraAclaris Therapeutics, Inc. · Dermatosis Papulosa NigraCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 25, 2019ActualPhase 2NCT03585296A Study of ATI-502 Topical Solution for the Treatment of Atopic DermatitisAclaris Therapeutics, Inc. · Atopic DermatitisCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 6, 2018ActualPhase 2NCT03551821Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia AreataAclaris Therapeutics, Inc. · Alopecia AreataCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2018ActualPhase 4NCT03487588An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic KeratosesAclaris Therapeutics, Inc. · Seborrheic KeratosisCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2018ActualPhase 4NCT03380390Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With RosaceaAclaris Therapeutics, Inc. · RosaceaCompletedACRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 12 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner